for people ages 18-80 (full criteria)
at Irvine, California and other locations
study started
estimated completion
Principal Investigator
by Namita Goyal



ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is a 48-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be a 44-week active treatment extension (ATE) during which all subjects will receive ABBV-CLS-7262. Subjects will attend regular visits during the course of the study and complete medical assessments, blood tests, checking for side effects, and completing questionnaires.

Official Title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of ABBV-CLS-7262 in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension


ALS, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Sclerosis, ABBV-CLS-7262


You can join if…

Open to people ages 18-80

  • Must have an identified, reliable caregiver
  • Confirmed diagnosis of Familial ALS or Sporadic ALS
  • First ALS symptoms occurred ≤36 months before screening
  • Able to swallow solids
  • No known active COVID-19 infection at screening
  • Vital capacity ≥50% predicted value (for sex, age, ethnic origin, and height) at screening
  • Subjects must be a) naïve to, or b) off riluzole (Rilutek), or c) on a stable dose >30 days prior to Baseline visit to enter study
  • Subjects must be a) naïve to, or b) off edaravone (Radicava), or c) have completed 2 treatment cycles prior to the Baseline visit.

You CAN'T join if...

  • History of dementia/severe cognitive problems at screening
  • Use of riluzole (Rilutek®) if dose has NOT been stable for > 30 days prior to Baseline visit
  • History of clinically significant medical conditions (other than ALS) or any other reason, including any physical, psychological, or psychiatric condition that, in the opinion of the Investigator, would compromise the safety or interfere with the subject's participation in the study, or would make the subject an unsuitable candidate to receive study drug, or would put the subject at risk by participating in the study.
  • History of abnormal screening laboratory or imaging results that, in the opinion of the Investigator, are indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease that would preclude administration of ABBV-CLS-7262.
  • If female, is known to be pregnant, breastfeeding, considering becoming pregnant, or donating/banking eggs during the study or within 30 days or >5 half-lives (whichever is longer) after the last dose of study drug
  • If male, plans to donate sperm or father a child during the study or within 30 days after the last dose of study drug.
  • Known to have received any investigational product within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
  • History of ABBV-CLS-7262 use prior to participation in this study
  • Recent (within 6 months prior to Screening) history of drug or alcohol abuse
  • Previous participation in a stem cell clinical study
  • Current or anticipated use of diaphragmatic pacing during the study period
  • Tracheostomy or use of non-invasive ventilatory support ≥22 hours a day


  • UC Irvine Health ALS and Neuromuscular Center accepting new patients
    Irvine California 92868 United States
  • Forbes Norris MDA/ALS Research and Treatment Center accepting new patients
    San Francisco California 94109 United States

Lead Scientist at UC Irvine

  • Namita Goyal
    Health Sciences Professor, Neurology, School of Medicine. Authored (or co-authored) 41 research publications


accepting new patients
Start Date
Completion Date
Calico Life Sciences LLC
Phase 1 Amyotropic Lateral Sclerosis (ALS) Research Study
Study Type
Expecting 30 study participants
Last Updated